Faeth Therapeutics Return on Equity

Faeth Therapeutics (FTH) currently reports a ROE of -113.05%. That is below the Healthcare sector average of -75.59%. Use the charts on this page to explore Faeth Therapeutics's ROE history and peer comparisons.

Faeth Therapeutics's ROE of -113.05% is lower than the Healthcare sector average of -75.59%. That is roughly 49.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Faeth Therapeutics's current -113.05% should be judged against Healthcare norms (sector average: -75.59%) and against FTH's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -113.05%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.59%. From there, open related valuation or income-statement pages for Faeth Therapeutics, and consider following FTH for alerts when major investors trade the stock.

Faeth Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -113.05% versus a sector average near -75.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FTH with unrelated industries.